Berlinger Provides Launch Video of its New Anti-Doping Security Bottles

Food and Healthcare Press Releases Friday August 25, 2017 08:08
GANTERSCHWIL, Switzerland--25 Aug--PRNewswire/InfoQuest

Berlinger Special AG has placed a launch video on its corporate website ( http://www.berlinger.com/geneva-video ) featuring the first-ever images of its new BEREG-KIT Geneva security bottles for anti-doping samples.

(Logo: http://mma.prnewswire.com/media/548750/Berlinger_Special_AG_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/548751/Produktion_Berlinger_Special_AG.jpg )

As announced in June, Swiss tech company Berlinger Special AG is introducing a new generation this autumn of its BEREG-KIT security bottles, which are used all over the world to help prevent doping in sports (see also the media release of 15 June 2017, which will be found at http://www.berlinger.com/media-releases ).

The company, which is based in Ganterschwil in Eastern Switzerland, has now produced a launch video of its new BEREG-KIT Geneva featuring the first-ever official images of the new anti-doping security bottles. Production of the new bottles will commence in early September, and from then onwards the BEREG-KIT Geneva will be available to all Berlinger Special AG customers worldwide.

You can view the launch video here:
( http://www.berlinger.com/geneva-video )
You will find FAQs on the new BEREG-KIT Geneva here:
( http://www.berlinger.com/geneva-FAQ )
Further information:
Berlinger Special AG
Media Relations
c/o KLAUS METZLER ECKMANN SPILLMANN
Hans Klaus, media spokesman
Basteiplatz 7
CH-8001 Zurich
Phone: +41-43-544-1744
Mobile: +41-79-357-0357
Email: klaus@kmespartner.com
Source: Berlinger Special AG

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics